



February 6, 2024

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Unaudited Financial Results for the quarter ended December 31, 2023 and Interim Dividend for Financial Year 2023-24

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 1.15 p.m. and ended at 4:22 p.m.), the Unaudited Financial Results for the quarter ended December 31, 2023 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended December 31, 2023;
- b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2023 furnished by Statutory Auditors of the Company.

Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have declared an Interim Dividend for the Financial Year 2023-24 of ₹ 200 (including one-time special dividend of Rs. 150) per Equity Share having face value of Rs. 10/- each. The dividend shall be paid on or before March 3, 2024.

As informed earlier in our letter dated January 25, 2024, record date for the purpose of eligibility for payment of said Interim Dividend shall be February 14, 2024.

Kindly take the same on record and oblige.

Thanking you,
Yours faithfully,

For Procter & Gamble Health Limited

Zeal Rupani
Company Secretary

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 31 DECEMBER 2023

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)	(6)
		Three months ended 31st December 2023 (Unaudited)	Preceding Three months ended 30th September 2023 (Unaudited)	Corresponding Three months ended 31st December 2022 (Unaudited)	Half Year ended 31st December 2023 (Unaudited)	Half Year ended 31st December 2022 (Unaudited)	Year ended 30th June 2023 (Audited)
1.	Revenue from Operations	30,997	30,493	30,997	61,490	60,752	122,962
2.	Other Income	518	605	454	1,123	796	1,839
3.	Total income (1+2)	31,515	31,098	31,451	62,613	61,548	124,801
4.	Expenses						
	a) Cost of materials consumed	7,084	8,731	10,108	15,815	18,130	31,923
	b) Purchases of stock-in-trade	840	142	773	982	1,289	3,976
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	1,115	(159)	(2,739)	956	(2,628)	285
	d) Employee benefits expense	5,743	6,064	4,726	11,807	9,004	20,617
	e) Depreciation and amortisation expense	692	648	823	1,340	1,571	2,810
	f) Impairment / (Reversal)	-	-	152	-	152	(73)
	g) Finance Costs	19	18	23	37	39	77
	h) Other expenses	6,050	6,849	7,091	12,899	14,837	33,766
	Total expenses (4)	21,543	22,293	20,957	43,836	42,394	93,381
5.	Profit before exceptional items and tax (3-4)	9,972	8,805	10,494	18,777	19,154	31,420
6.	Less: Exceptional items	-	-	-	-		-
7.	Profit before tax (5-6)	9,972	8,805	10,494	18,777	19,154	31,420
8.	Tax expenses						
	Current Tax	2,772	2,229	3,006	5,001	5,197	8,661
	Deferred Tax	(191)	19	(192)	(172)	(89)	(506)
	Tax for earlier years	184	-	-	184	-	318
9.	Net Profit for the period/ year (7-8)	7,207	6,557	7,680	13,764	14,046	22,947
10.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains/(losses) on defined benefit plans	115	(68)	(564)	47	(541)	(246)
	ii. Income tax effect	(29)	17	142	(12)	136	62
	Total Other Comprehensive Income, net of tax	86	(51)	(422)	35	(405)	(184)
11.	Total Comprehensive Income for the period/year (9+10)	7,293	6,506	7,258	13,799	13,641	22,763
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660	1,660	1,660	1,660	1,660	1,660
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	-	-	73,429
14.	Earnings per equity share (of Rs 10/- each) *(not annualised)						
	(a) Basic and Diluted (in Rs.)	* 43.4	* 39.5	* 46.3	* 82.9	* 84.6	138.2

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

Notes:

1. The above results have been reviewed by Audit Committee and approved by the Board of Directors of the Company at meeting held on February 6, 2024 and have been subjected to a limited review by the Statutory Auditors of the Company.
2. Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
3. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.
4. The Board of Directors at its meeting held on February 6, 2024 have declared for the current year an interim dividend of ₹ 200 per equity share of face value ₹ 10 each (including a one-time special dividend of ₹ 150 per equity share) aggregating to ₹ 33,199 lakhs.
5. During the Quarter, certain employees opted for the Company's existing voluntary retirement scheme. Employee cost includes expense amounting to ₹ 1,180 lakhs (For previous quarter ended 30th September 2023 expense of ₹ 1,447 lakhs) in this regard.

For and on behalf of the Board of Directors of
Procter & Gamble Health Limited.

Milind Vasant
Thatte

Digitally signed by Milind
Vasant Thatte
Date: 2024.02.06 16:07:45
+05'30'

Milind Thatte
Managing Director

Place : Goa

Date : February 6, 2024

Please visit us at our website www.pghealthindia.com

PROCTER & GAMBLE HEALTH LIMITED

Notes:

1. Statement of Assets and Liabilities

(₹ in lakhs)

	As at December 31, 2023 [Unaudited]	As at June 30, 2023 [Audited]
ASSETS		
Non-current assets		
(a) Property, plant and equipment	13,027	12,964
(b) Capital work-in-progress	2,808	3,249
(c) Investment property	208	225
(d) Right-of-use assets	979	1,114
(e) Intangible assets	70	94
(f) Financial assets		
(i) Loans	813	630
(ii) Other financial assets	530	509
(g) Deferred tax assets (Net)	2,692	2,532
(h) Other non-current assets	911	930
(i) Non-current tax assets (Net)	8,542	8,262
Total non-current assets	30,580	30,509
Current assets		
(a) Inventories	12,905	13,494
(b) Financial assets		
(i) Trade receivables	13,576	11,571
(ii) Cash and cash equivalents	42,061	43,505
(iii) Bank balances other than (ii) above	495	517
(iv) Loans	139	153
(v) Other financial assets	799	1,256
(c) Other current assets	7,150	9,114
Total current assets	77,125	79,610
TOTAL ASSETS	107,705	110,119
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,660	1,660
(b) Other equity	78,928	73,429
Total Equity	80,588	75,089
Non-Current Liabilities		
(a) Financial liabilities		
(i) Lease liabilities	803	888
(b) Provisions	3,197	3,687
(c) Other non-current liabilities	67	65
Total non-current liabilities	4,067	4,640
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
- Total outstanding dues of micro enterprises and small enterprise	1,108	991
- Total outstanding dues of creditors other than micro enterprises and small enterprises	16,053	22,713
(ii) Lease Liabilities	277	312
(iii) Other financial liabilities	3,049	3,044
(b) Provisions	781	1,824
(c) Current tax liabilities (net)	407	613
(d) Other current liabilities	1,375	893
Total current liabilities	23,050	30,390
TOTAL EQUITY & LIABILITIES	107,705	110,119

Procter & Gamble Health Limited

Cash Flow Statement

	(Unaudited) Half Year ended Dec 31, 2023 ₹ in lakhs	(Audited) Year ended June 30, 2023 ₹ in lakhs
A. Cash Flows from Operating Activities		
Profit before tax	18,777	31 420
Adjustments for:		
Net unrealised foreign exchange loss	(95)	45
Allowance for doubtful receivables/ other assets	(72)	215
Inventory written off	(447)	1 266
Provision/ write off of GST and other taxes	615	1 431
Depreciation of property, plant and equipment	1,340	2 810
Provision for Impairment	-	(73)
Income from letting of office premises	(103)	(205)
Provision for employee benefits	442	(271)
Provision for sales return/ expiries	(1,092)	302
Loss/(Profit) on sale of property, plant and equipment	34	(71)
Share-based payment to employees	-	56
Finance Cost	37	77
Interest income	(882)	(1 433)
Operating profit before working capital changes	18,554	35 569
Working capital adjustments:		
Decrease/(Increase) in inventories	1,036	(3 239)
(Increase)/Decrease in trade receivables	(1,922)	(3 292)
Decrease/(Increase) in financial and other Assets	1,557	(3 184)
(Increase)/Decrease in trade payables	(6,424)	6 392
Decrease/(Increase) in other liabilities and provisions	334	321
Cash generated from operations	13,135	32 566
Income taxes paid (net)	(5,671)	(8 966)
Net cash generated from operating activities (A)	7,464	23 600
B. Cash Flows from Investing Activities		
Purchase and construction of property, plant and equipment	(1,504)	(4 248)
Proceeds from sale of asset	7	474
Income from letting of office premises	103	205
Interest received	940	1 419
Net cash (used in)/ generated from investing activities (B)	(454)	(2 150)
C. Cash flow from financing activities		
Dividend paid	(8,299)	(9 379)
Payment of lease liability	(156)	(468)
Net cash flow used in financing activities (C)	(8,455)	(9 847)
Net (decrease)/ increase in cash and cash equivalents (A+B+C)	(1,446)	11 602
Cash and cash equivalents at the beginning of the year	43,542	31 940
Cash and cash equivalents at the end of the year	42,097	43 542
Components of Cash and Cash equivalents:		
Balance with Banks		
In Current accounts	9,097	9 542
In Term deposits (less than 3 months maturity)	33,000	34 000
	42,097	43 542

Note:

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

HARIBHAKTI & CO. LLP

Chartered Accountants

Independent Auditor's Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended)

To the Board of Directors

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited ("the Company") for the quarter ended December 31, 2023 and for the period from July 01, 2023 to December 31, 2023 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as "the said Indian Accounting Standard") and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles

HARIBHAKTI & CO. LLP

Chartered Accountants

generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048

DEEPAK
G
MOROLIA

Digitally signed
by DEEPAK G
MOROLIA
Date: 2024.02.06
16:18:29 +05'30'

Deepak G. Morolia

Partner

Membership No.:130533

UDIN: 24130533BKFEBP1694

Place: Mumbai

Date: February 06, 2024